尿激酶治疗肺栓塞患者的安全性及有效性临床分析

目的探讨尿激酶治疗肺栓塞的安全性及有效性。方法选取本院2010年10月~2013年10月诊治的肺栓塞患者130例,采用数字随机法分为两组,对照组65例患者采用低分子肝素和华法林治疗,观察组65例患者采用低分子肝素、尿激酶、华法林治疗,采用MRC评分评定患者的呼吸困难程度,比较两组的临床疗效、相关指标的改变情况。结果两组治疗后的组织型纤溶酶原激活物活性、D-二聚体含量、纤溶酶原激活物特异性抑制因子活性、MRC评分均显著降低,血氧饱和度显著升高,差异有统计学意义（P〈0.05）。观察组治疗后的组织型纤溶酶原激活物活性、D-二聚体含量、纤溶酶原激活物特异性抑制因子活性、MRC评分均明显低于对照组,血氧饱和度、总有效率均明显高于对照组,差异有统计学意义（P〈0.05）。结论尿激酶是治疗肺栓塞的有效药物,可明显改善患者的相关临床指标和呼吸困难程度,疗效显著,值得临床推广应用。

Clinical analysis of safety and efficacy of urokinase in the treatment of patients with pulmonary embolism

Objective To investigate safety and efficacy of urokinase in the treatment of pulmonary embolism. Methods 130 cases of patients with pulmonary embolism were selected in hospital from October 2010 to October 2013,who were randomly divided into two groups.Low molecular weight heparin and warfarin regimen were used in control group（65 cases）,low molecular weight heparin,urokinase and warfarin regimen were used in observation group（65 cases）.Degree of dyspnea was evaluated by MRC score.Change of related index and clinical efficacy was compared between two groups respectively. Results After treatment,t-PA activity,D-D content,PAI activity,MRC score significantly decreased while oxygen saturation significantly increased in two groups respectively,with statistical difference（P〈0.05）.After treatment,t- PA activity,D-D content,PAl activity,MRC score in observation group was significantly lower than that in control group respectively,oxygen saturation and total efficiency rate in observation group was significantly higher than that in control group respectively,with statistical difference （P〈0.05）. Conclusion Urokinase is an effective drug in the treatment of pulmonary embolism,which can significantly improve related clinical index and degree of dyspnea in patient.Urokinase has significant clinical efficacy,which is worthy of clinical promotion and application.